Quay Pharma is now part of sgs logoopens in a new window

OUR CONTRACT PHARMACEUTICAL SERVICES

Company Overview

PRECLINICAL FORMULATION SCREENING

We create robust formulation development strategies tailored to the characteristics of each individual API.

Read MoreWatch Now

Quay Pharma enjoys the opportunity to engage with our clients as early as possible to create robust development strategies tailored to the characteristics of each individual API.

To that end, Quay Pharma can complement the drug discovery process by optimising dosing formulations ahead of efficacy, pharmacokinetic and toxicological preclinical studies by assessing solubility and short-term stability using minimal API. Utilising a rapid turnaround and cost-effective screening platform, the selection of solvents and/or excipients will be tailored to the individual API depending on critical factors such as indication, route of administration and intended species. By optimising formulation at this stage, bioavailability profiles can be improved and the exposure levels achieved during toxicology studies can be enhanced.

We can incorporate rodent PK assessment for formulation compa